A rare paraneoplastic condition in Hodgkin lymphoma: Evans syndrome and literature review.
Autoimmune hemolytic anemia
Evans syndrome
Hodgkin lymphoma
immune thrombocytopenia
Journal
Northern clinics of Istanbul
ISSN: 2536-4553
Titre abrégé: North Clin Istanb
Pays: Turkey
ID NLM: 101684520
Informations de publication
Date de publication:
2024
2024
Historique:
received:
23
08
2022
accepted:
10
10
2022
medline:
21
10
2024
pubmed:
21
10
2024
entrez:
21
10
2024
Statut:
epublish
Résumé
Evans syndrome (ES) is a spectrum of diseases in which the combination of autoimmune hemolytic anemia and immune thrombocytopenia or sometimes neutropenia. ES has been accepted usually as an idiopathic condition, but it may be secondary. The coexistence of autoimmune cytopenias and Hodgkin lymphoma (HL) is rarely observed and the rate of ES in HL patients is not clear. Here we describe a 56-year-old male patient who presented with ES and was diagnosed with HL. After corticosteroids, intravenous immunoglobulin (IVIG) and ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) treatment, immune cytopenias were completely resolved. The literature is also reviewed and we found 16 cases in which HL and ES coexist. Although AIHA and immune thrombocytopenia usually develop simultaneously, they rarely occur at different times. Many aspects of the pathogenesis are unknown, but it is thought to be a complex immunological background. Corticosteroids and/or IVIG are the most commonly used first-choice drugs in the initial treatment of ES. Response rates to treatment are variable and response to treatment may be poor, particularly with underlying conditions. If detected, the underlying lymphoma should be treated.
Identifiants
pubmed: 39431027
doi: 10.14744/nci.2022.66742
pii: NCI-11-488
pmc: PMC11487318
doi:
Types de publication
Case Reports
Journal Article
Langues
eng
Pagination
488-491Déclaration de conflit d'intérêts
No conflict of interest was declared by the authors.